Ohio State University Comprehensive Cancer Center
Clinical Trials
331
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (290 trials with phase data)• Click on a phase to view related trials
A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer
- Conditions
- Localized Pancreatic Ductal AdenocarcinomaStage 0 Pancreatic Cancer AJCC v8Stage I Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Target Recruit Count
- 25
- Registration Number
- NCT07124611
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Studying Flavors and Cooling Agents in Oral Nicotine Pouches to Understand User Preferences
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Procedure: Carbon Monoxide MeasurementOther: Questionnaire AdministrationDrug: Smoke usual brand cigarette
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Target Recruit Count
- 30
- Registration Number
- NCT07111234
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stress (FOCUS)
- Conditions
- Lung CancerMultiple MyelomaBreast CancerProstate CancerMelanoma
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-07
- Target Recruit Count
- 120
- Registration Number
- NCT07102212
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Studying the Effects of Nicotine Concentration and Flavor on Alcohol Use in Young Adults
- Conditions
- Alcohol-Related Carcinoma
- Interventions
- Other: Ecological Momentary AssessmentOther: MonitoringOther: Survey Administration
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Target Recruit Count
- 20
- Registration Number
- NCT07095140
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
- Conditions
- Recurrent Malignant GliomaRecurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 GliomaWHO Grade 2 GliomaWHO Grade 3 GliomaWHO Grade 4 Glioma
- Interventions
- Biological: Anti-GARP Chimeric Antigen Receptor-T CellsProcedure: Biospecimen CollectionProcedure: Chest RadiographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: PheresisProcedure: Surgical Procedure
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-07-09
- Target Recruit Count
- 30
- Registration Number
- NCT06964737
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 67
- Next
News
TAE Life Sciences and Ohio State University Partner to Advance Boron Neutron Capture Therapy for Cancer Treatment
TAE Life Sciences and Ohio State University have formed the first U.S.-based academic-industry alliance focused on developing novel boron-based drug compounds for Boron Neutron Capture Therapy (BNCT).
ACCC Fall 2024: Innovations in Clinical Trial Access, Patient Care, and Treatment Authorization
The Ohio State University Cancer Center's automated informatics program has achieved a 21.9% increase in biosimilar utilization while streamlining prior authorization processes, earning an Innovator Award at ACCC 2024.
First-in-Human Trial Launched for Novel DHODH Inhibitor HOSU-53 in Solid Tumors and Lymphomas
A Phase I/II clinical trial is set to begin at Ohio State University, evaluating the novel DHODH inhibitor HOSU-53 in patients with advanced solid tumors and Non-Hodgkin's lymphoma.
Nanopharmaceutics Completes Enrollment in Phase 2 Neuroendocrine Tumor Study Combining Triapine with Lutetium Lu 177 Dotatate
Nanopharmaceutics has completed patient enrollment in a 94-patient Phase 2 randomized controlled trial evaluating Triapine plus lutetium Lu 177 dotatate versus standard therapy alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors.